Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
CNS: Fiscal 2004 revenue expected to increase 10%-13% to $85 mil.-$90 mil., President & CEO Marti Morfitt tells analysts during March 20 conference call. Morfitt projects sales growth should come from four areas noting CNS' domestic Breathe Right nasal strip, FiberChoice businesses will increase 2%-4%, while international sales should rise 10%-18%. CNS anticipates Breathe Right Snore Relief Throat Spray, which launched in mid-2002, will grow another $1 mil.-$3 mil. in sales over FY 2003, and the firm's new Breathe Right Vapor Shot! vaporizer is expected to add $4 mil.-$7 mil. in new product revenue (1"The Tan Sheet" March 17, 2003, p. 19). CNS plans to increase domestic Breathe Right ad expenditure by 10% to $22 mil., to be "split between our snoring message and our nasal congestion message," Morfitt says...